Neurocrine Biosciences (NBIX) Tops Q3 EPS by 49c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $161.71 +0.06%
Revenue Growth %: +26.4%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +26.4%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.54, $0.49 better than the analyst estimate of $1.05. Revenue for the quarter came in at $498.8 million versus the consensus estimate of $478.85 million.
GUIDANCE:
Neurocrine Biosciences sees FY2023 revenue of $1.82-1.84 billion, versus the consensus of $1.86 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
- Goldman "broadly" raises estimates for LTL and truckload stocks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
